Minister for Jobs, Enterprise, and Innovation Mary Mitchell O’Connor TD has announced that Takeda Pharmaceutical Company will invest €40m in a new facility at their Grange Castle site in Dublin.

Takeda’s investment will expand the site’s existing footprint, with the construction of a new standalone high-containment production facility dedicated to manufacturing its oncology product NINLAROTM for global markets. The investment will create approximately 40 new jobs.

Takeda first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002, Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan.

Welcoming the new investment, Minister Mitchell O’Connor said: "The pharmaceutical industry makes a huge contribution to the Irish economy in terms of jobs and exports and is one of the fastest growing sectors.

"Takeda’s decision to manufacture their new cancer treatment in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here.

"I’m delighted that this investment will bring a further 40 jobs to the company’s existing Clondalkin facility".
Plant Director at Takeda Ireland Grange Castle Mr. Paul Keogh said: "We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide.

"We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high-quality products from our site".

Commenting on the investment, chief executive officer (CEO) of IDA Ireland Martin Shanahan said: "Ireland is a globally recognised centre of excellence in life sciences due to the country’s strong regulatory track record and talent availability.

"Today’s investment by Takeda demonstrates their continued commitment to Ireland. I wish the Takeda team every success as they continue to grow their operations in Ireland."